多剂量随机II期剂量优化试验的设计与样本量确定
本文针对FDA Project Optimus提出的多剂量随机II期剂量优化试验,推广了I类错误和把握度的标准定义,推导了决策规则与确定最优样本量的算法,形成MERIT设计。模拟研究显示该设计具有良好运行特征,每个剂量组20至40例样本量常能提供合理的把握度和I类错误。
要点
- FDA Project Optimus倡导剂量选择从最大耐受剂量转向最优风险获益权衡。
- MERIT设计推广了I类错误和把握度定义并给出确定最优样本量的算法。
- 模拟研究显示每个剂量组20至40例常能提供合理的把握度和I类错误。
核心结论
- MERIT设计在模拟研究中具有良好运行特征,每剂量组20至40例常能提供合理的把握度和I类错误以确保患者安全与获益。
研究设计与样本
- 本文聚焦于I期试验完成后开展的多剂量随机II期试验设计,通常比较最大耐受剂量及低于最大耐受剂量的一或两个剂量,以确定最大化获益风险权衡的最优剂量。
主要发现
- 模拟研究表明MERIT设计具有良好运行特征,每个剂量组20至40例样本量常能提供合理的把握度和I类错误。
关键数值与推荐
- 本文推广了I类错误和把握度的标准定义以适应剂量优化的独特特征,并推导了决策规则及确定最优样本量的算法。
- 所形成设计称为MERIT(基于毒性和疗效的剂量优化多剂量随机试验设计)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The U.S. Food and Drug Administration (FDA) has launched Project Optimus to shift dose selection from the maximum tolerated dose (MTD) to the dose that produces the optimal risk-benefit tradeoff. One approach highlighted in the FDA's guidance involves conducting a randomized phase II trial following the completion of a phase I trial, where multiple doses (typically including the MTD and one or two doses lower than the MTD) are compared to identify the optimal dose that maximizes the benefit-risk tradeoff. This article focuses on the design of such a multiple-dose randomized trial, specifically the determination of the sample size. We generalized the standard definitions of type I error and power to accommodate the unique characteristics of dose optimization and derived a decision rule along with an algorithm to determine the optimal sample size. The resulting design is referred to as MERIT (Multiple-dosE RandomIzed Trial design for dose optimization based on toxicity and efficacy). Simulation studies demonstrate that MERIT has desirable operating characteristics, and a sample size between 20 and 40 per dosage arm often offers reasonable power and type I errors to ensure patient safety and benefit. To facilitate the implementation of the MERIT design, we provide software, available at https://www.trialdesign.org.
引用
- Yang P, Li D, Lin R, et al. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Stat Med. 2024. PMID: 38747472. doi:10.1002/sim.10093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。